Worth reading
13Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.This transaction
Corporate Name ChangeTimelineThe spacing between the points is proportional to the actual number of days.White points represent dates designated as scheduled dates in the document.
Procedures and assumptions
Conditions Precedent to ExecutionApproval of a partial amendment to the Articles of Incorporation at the 46th Annual General Meeting of Shareholders scheduled for 26 June 2026
Management structure after acquisitionThe corporate name will be changed to JLL Med Inc. (English name: JLL Med Inc.). The treatment of the representative and employees is Not disclosed
| Item | Details |
|---|---|
| Transaction name | Corporate Name Change |
| Date of board resolution | 26 May 2026 |
| Execution Date / Effective Date | 1 March 2027 (予定). Subject to approval of the amendment to the Articles of Incorporation at the Annual General Meeting of Shareholders scheduled for 26 June 2026 |
| Conditions Precedent to Execution | Approval of a partial amendment to the Articles of Incorporation at the 46th Annual General Meeting of Shareholders scheduled for 26 June 2026 |
| Management structure after acquisition | The corporate name will be changed to JLL Med Inc. (English name: JLL Med Inc.). The treatment of the representative and employees is Not disclosed |
Items this document does not state (27)
Counterparty nameName of the Subject CompanyBusiness Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Impact on Business PerformanceContract DateValuation methodologyIndependent valuation institutionSpecial Committee
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To accelerate its transformation into a global medical device manufacturer and demonstrate its transformation into a company that contributes to the health and lives of people around the world, not only in Japan.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.